ISO 9001:2015 and ISO 13485:2016, a new re-certification!

Emosis is proud to announce that company’s certification under the norms ISO 13485:2016 and ISO 9001:2015 is maintained for the fourth year!

This achievement underscores that Emosis demonstrates the sustained focus and vision required to maintain and continually improve company’s ISO-based quality management system (QMS).

It is a critical step to successfully prepare forthcoming audit and (re-)certification of Emosis products by a Notified Body according to the new EU legislation applicable to in vitro diagnostic (IVD) medical devices, Diagnostic Regulation (IVDR) (EU) 2017/746.

This regulation that considerably strengthen the emphasis on certain essential aspects of the CE marking regulatory process, such as risk-based classification, conformity assessment and product certification including performance assessment by third-party independent Notified Bodies designed by the Competent Authorities of each EU member state, and post-market performance surveillance and reactovigilance.

We are thankful to our teams that are already committed to develop Emosis products consistently with the requirements of this new regulation which will ultimately improve the quality of care for the patients.

Download ISO 9001 certificate - Download ISO 13485 certificate

May patients be subject to hit because of SARS-CoV-2? A prospective study answers the question.

Conducted in France and Switzerland by the Hospital of Lariboisière Paris and the University Hospital of Geneva, the study on hospitalized SARS-CoV-2-infected patients has just been published in Thrombosis & Haemostasis journal (December issue)..

In hospitalized SARS-CoV-2-infected patients, elevated prevalence of thromboembolic events (TE) has been reported with subsequent recommendations to reinforce prophylactic anticoagulation using low-molecularweight (LMWH) or unfractionated-heparin (UFH).

For each patient referred by the attending physician for HIT suspicion, Lariboisière and Geneva Hospitals performed tests among which the HIT ConfirmTM test developed by Emosis.

Finally, the study suggests that COVID-19 patients receiving LMWH do not appear to be especially susceptible to HIT. Prevalence of HIT-associated antibodies is comparable to other critical illness settings and those antibodies do not seem to be associated with increased risk of TE and death.

To read more, please click on following link Thieme E-Books & E-Journals - Thrombosis and Haemostasis / Issue (

Paving the way for further development of human-centered artificial intelligence toward augmented blood testing

Grateful to JIB 2020 for the opportunity of sharing Emosis’s seminal work on AI-related machine learning algorithms for augmenting the diagnostic performance of in vitro testing, for the benefit of clinical lab specialists and practitioners managing patients with cardioneurovascular diseases.

At Emosis, we strongly believe that the future of augmented IVDx-AI is human-centered, statistical relational (StarAI) and explainable to address the ethical imperative.

For more information (poster in French presented in JIB 2020), click here.

Préparer le développement d’une IA augmentant les capacités des biologistes médicaux à informer la décision clinique, au bénéfice des patients souffrant de maladies cardioneurovasculaires.
Nos remerciements aux JIB 2020 d’avoir permis à Emosis de partager ses premiers résultats.

Chez Emosis, nous croyons que le futur de l’IA en biologie médicale, porteur de l’espoir de diagnostics augmentés, sera coopérative et non substitutive, fusionnera analyse des données et statistiques, et satisfera l’impératif éthique par son explicabilité.

Pour plus d’informations, cliquez ici pour découvrir le poster présenté aux JIB 2020.

How does Emosis deal with Covid-19? An interview of Frédéric Allemand on B Smart TV

Frédéric Allemand, co-founder and CEO of Emosis, answered famous journalist Jean-Marc Sylvestre questions on the brand-new business TV channel B Smart.

Discover the interview (in French - duration: 5 minutes) :


Erba Group will distribute Emosis products in Russia, Ukraine, Belarus, Uzbekistan and Kazakhstan

Emosis and Erba Group’s subsidiary Erba RUS have signed a partnership for the distribution of Emosis HIT Confirm® and future Emo-tests in Russia and Ukraine (exclusive basis) and Belarus, Uzbekistan and Kazakhstan (non-exclusive basis).

Erba Group is an emerging in vitro diagnostic international player which is offering a full range of products addressing most clinical laboratory’s needs.